CellCept® Has Positive Results in Phase III Lupus Nephritis Trial
Maintenance phase of Aspreva Lupus Management Study (ALMS) successfully achieves primary endpoint
Vifor Pharma, the pharma business sector of the Galenica Group, and Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the maintenance phase of the Aspreva Lupus Man-agement Study (ALMS) has successfully achieved its primary endpoint. The trial demonstrates the superiority of Roche's CellCept® (mycophenolate mofetil) versus azathioprine (AZA) in de-laying treatment failure in patients with Lupus Nephritis (LN). ALMS is one of the largest studies ever conducted in LN.